Navigation Links
Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly's Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
Date:9/26/2013

or patients with type 2 diabetes."

The patient-reported outcomes from the AWARD-1 trial showed that treatment satisfaction, as measured by the DTSQ, was significantly higher with dulaglutide compared to baseline, and was significantly greater compared to placebo and exenatide twice-daily at 26 weeks. Significant improvements were also seen compared to baseline and exenatide twice-daily at 52 weeks.2

Clinical results from the AWARD-1 trial showed that treatment with dulaglutide 1.5 mg led to improvements in HbA1c levels and weight reductions.1 Dulaglutide-treated patients also demonstrated significant improvements compared to baseline and exenatide twice-daily in perceived hyperglycaemia scores (using DTSQ) at 26 and 52 weeks.2

Patients in the study noted significant improvements in weight-related self-perception (IW-SP) compared to baseline at 26 weeks, which persisted through one year of treatment. These improvements were not significantly different between all treatment groups.2 There were no significant differences in the ability to perform physical activities of daily living (APPADL) between dulaglutide-treated patients compared to baseline, placebo or exenatide-treated patients.2

Treatment with dulaglutide, as well as with exenatide twice-daily, led to significant improvements in perceptions of current health status (EQ-5D) compared to baseline at 26 weeks; these improvements with dulaglutide 1.5 mg as well as exenatide twice-daily were also significant compared to placebo. Significant improvements were also seen compared to baseline at one year, with no significant differences between dulaglutide and exenatide twice-daily.

In the clinical trial, gastrointestinal-related symptoms, including nausea, vomiting and diarrhoea, were the most common adverse events reported for dulaglutide and were mostly mild to moderate and transient.  

Dulaglutide is one of sever
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
7. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
10. Body Monitors Deliver Better Weight Loss Results at Half the Cost: Study to Be Presented at ACSM Meeting
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Electrocardiogram (ECG) Devices - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... US$330 million by 2016. The North America ... global market share while Europe ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... April 27, 2012  Hill-Rom Holdings, Inc. (NYSE: HRC ... the Deutsche Bank Securities Health Care Conference in Boston on ... are invited to listen to the live discussion via the ... at http://www.media-server.com/m/p/2sfzaj9g . A recorded replay of the discussion ...
... Presented today by Tribeca Film Festival co-founder Craig ... Professor Clay Christensen and the Disruptor Foundation, Hanger ... CP, FAAOP and Area Practice Manager Dan Strzempka, ... Award.  Carroll and Strzempka received the award for ...
Cached Medicine Technology:Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award 2
(Date:12/17/2014)... This prestigious award is given ... made outstanding and innovative contributions to the physical ... private practice physical therapy by the Private Practice ... On behalf of Performance Physical Therapy, Michelle Collie ... Performance accepted the award at the Private Practice, ...
(Date:12/17/2014)... 17, 2014 In its comprehensive analysis ... its Argus Claim Review division have recently identified out-of-network ... common ways savings are achieved on behalf of employer-clients. ... of dollars in savings to Argus each year, with ... As explained by Tom Doney, Cypress president and CEO, ...
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Expectant parents should leave prenatal ... Administration recommends. Use of ultrasound imaging and heartbeat ... entirely risk-free, the agency warns. "Although there ... to ultrasound imaging and heartbeat monitors, prudent use of ... Shahram Vaezy, an FDA biomedical engineer, said in an ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, 2014 ... a new study reveals that states that routinely perform randomized ... on their roads. The finding suggests that states that ... deter inebriated revelers from getting behind the wheel in the ... regarding drinking and driving," said study lead author James Fell, ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3
... proven effective, tamoxifen could be new way to fight ... drug used to help prevent recurring breast cancer appears to ... research has found. , University of Rochester Medical Center researchers ... infections, which can be fatal to people with compromised ...
... NEW YORK, July 24 Empire BlueCross BlueShield and Stony ... reached agreement for a new contract, effective August 1, 2009. ... access to Stony Brook Hospital as in-network. , ... the long-standing relationship we have with Stony Brook," noted Mark ...
... WASHINGTON, July 24 Speaker Nancy Pelosi issued ... to fund the Departments of Labor, Health and Human Services, Education, ... federal funding for needle exchange, passed in the House by a ... "The fiscal year 2010 Labor-Health and Human Services-Education appropriations ...
... , , WEST ... Hollywood will never go away. Despite the poor economy, a ... the American Society of Plastic Surgeons. One would think the ... to take better care of their skin, but unfortunately summertime in ...
... , , , PORTLAND, ... has selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for ... user the past several years due to its proven success and effectiveness ... , Dr. Vu commented, "Artefill is a great product for ...
... , , , LANCASTER, ... 32 filed cases around the country have filed a joint motion asking ... Judge James G. Carr of the United States District Court for the ... 2009, before the Judicial Panel on Multidistrict Litigation in Washington, D.C. , ...
Cached Medicine News:Health News:Breast Cancer Drug May Beat Fungal Infection 2Health News:Pelosi Statement on House Passage of Labor, HHS, Appropriations Bill, Which Lifts Ban on Needle Exchange 2Health News:It Isn't Just Vanity! Local MedSpa Seeks to Correct and Educate. 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio 2